No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALNY Alnylam Pharmaceuticals
- 143.310
- -0.400-0.28%
Close Apr 26 16:00 ET
- 146.130
- +2.820+1.97%
Post 17:12 ET
18.12BMarket Cap-40713P/E (TTM)
146.065High143.000Low479.14KVolume144.080Open143.710Pre Close69.17MTurnover0.38%Turnover RatioLossP/E (Static)126.45MShares218.88052wk High-82.13P/B18.04BFloat Cap141.97552wk Low--Dividend TTM125.91MShs Float242.970Historical High--Div YieldTTM2.13%Amplitude3.650Historical Low144.365Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Alnylam Pharmaceuticals Inc : JP Morgan Cuts Target Price to $166 From $170
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's (NYSE:ALNY) short percent of float has fallen 9.57% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 2.55% of all reg
Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsApr 18, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the lead
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Comments
Biotech Stock News 3/20
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Substantial insider selling of Alnylam Pharmaceuticals shares over the last quarter, with no recorded purchases, may suggest insiders think shares are not cheap. Insider ownership suggests alignment with shareholder interests, but history of sales warrants caution before buying.
1
Biotech Stock Catalyst Watchlist
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
15
Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3...
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3...
20
1
Ph2 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
23
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : 请问，ENDPQ重组后，持有的股票还能有效吗？